| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T4 |
0-205 |
Sentence |
denotes |
Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial. |
| T4 |
0-205 |
Sentence |
denotes |
Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved psoriatic arthritis signs and symptoms with an acceptable safety profile in a phase 2 trial. |
